Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek–Turkish collaborative study

One quarter of IBD patients requiring intensified anti-TNFa therapie were successfully deescalated to standard dosing, after a median of 16.0 (IQR: 8.0-36.0) months.

Authors

Institutions

Publication Details

Journal
European Journal of Gastroenterology & Hepatology
Published
2025-11-26
DOI
https://doi.org/10.1097/meg.0000000000003083
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek–Turkish collaborative study

Anǵeliki Theodoropoulou, Christos Liatsos, Magdalini Velegraki, Maria Tzouvala et al.
European Journal of Gastroenterology & Hepatology
Inflammatory Bowel Disease
article

Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek–Turkish collaborative study

Anǵeliki Theodoropoulou, Christos Liatsos, Magdalini Velegraki, Maria Tzouvala, Maria Kalogirou, Aykut Ferhat Çelık, George Tribonias, Ioannis Drygiannakis, Eirini Zacharopoulou, Dimitrios Christodoulou, Eftychia Tsironi, Όλγα Γιουλεμέ, Erasmia Vlachou, Georgia Tsiolakidou, Filiz Akyüz, Nikos Viazis, Nalan Gülşen Ünal, Andreas Kapsoritakis, Angeliki Christidou, Konstantina Paraskeva, Pelin Telli, Vasilios Papastergiou, Murat Törüner, Georgios Theocharis, Konstantina Dimopoulou, K Chalakatevaki, Konstantinos Κarmiris, Maria Palatianou, Ioannis E. Κoutroubakis, Konstantinos Argyriou, Charikleia Lamouri, Panagiotis Markopoulos, Panagiotis Kasapidis, Tarkan Karakan, Georgios Geramoutsos, Konstantinos Mousourakis, Evanthia Zampeli, Nikolaos Kyriakos, George Bamias, Atilla Akpınar, Κωνσταντίνος Κατσάνος, Fotios S. Fousekis, Evgenia Papathanasiou
article en

Abstract

One quarter of IBD patients requiring intensified anti-TNFa therapie were successfully deescalated to standard dosing, after a median of 16.0 (IQR: 8.0-36.0) months.

European Journal of Gastroenterology & HepatologyVol. 38(1)
Ankara University (TR), General University Hospital of Patras (GR), Ege University (TR), 401 General Military Hospital of Athens (GR), Istanbul University-Cerrahpaşa (TR), Alexandra Hospital (GR), Ippokrateio General Hospital of Thessaloniki (GR), Stavros (US), The General Hospital of Heraklion "Venizeleio-Pananio" (GR), Metaxa Hospital (GR), University Hospital of Heraklion (GR), General Hospital of Nikea (GR), University Hospital of Ioannina (GR), Agia Olga Hospital (GR), 404 General Military Hospital (GR), White Cross Court Rehabilitation Hospital (GB), Hippocration General Hospital (GR), Evangelismos Hospital (GR), Sotiria General Hospital (GR), Technological Educational Institute of Eastern Macedonia and Thrace (GR), Istanbul University (TR), Gazi University (TR)
Openalex Percentile: Top 60%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.